1-Year Results from a Phase 2 Study to Determine Safety and Tolerability of Treating Patients with Light-Chain (AL) Amyloidosis with Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia
Valent, Jason, Liedtke, Michaela, Zonder, Jeffrey A., Tulchinskiy, Mark, Udata, Chandrasekhar, Ramirez, Girly, Szymaniak, Kate, Catini, Julia, Quarta, Candida Cristina
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Cardiac Amyloid Reaching for Extended Survival (CARES): Study Design of Two Placebo-Controlled, Double-Blind, Randomized, International Phase 3 Trials Assessing Cael-101 in Patients with Mayo Stage Iiia or Stage IIIb AL Amyloidosis
Wechalekar, Ashutosh D., Silowsky, John, Daniel, Eileen, Harnett, Mark, Spector, Michael, Sobolov, Susan B., Quarta, Candida Cristina, Kurman, Michael R., Tulchinskiy, Mark, Bhattacharyya, Amit, Liedtke, Michaela
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article